Success Metrics

Clinical Success Rate
89.2%

Based on 189 completed trials

Completion Rate
89%(189/212)
Active Trials
94(23%)
Results Posted
10%(19 trials)
Terminated
23(6%)

Phase Distribution

Ph early_phase_1
2
0%
Ph phase_3
31
8%
Ph phase_2
30
7%
Ph phase_4
2
0%
Ph phase_1
2
0%
Ph not_applicable
41
10%

Phase Distribution

4

Early Stage

30

Mid Stage

33

Late Stage

Phase Distribution108 total trials
Early Phase 1First-in-human
2(1.9%)
Phase 1Safety & dosage
2(1.9%)
Phase 2Efficacy & side effects
30(27.8%)
Phase 3Large-scale testing
31(28.7%)
Phase 4Post-market surveillance
2(1.9%)
N/ANon-phased studies
41(38.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

189 of 216 finished

Non-Completion Rate

12.5%

27 ended early

Currently Active

94

trials recruiting

Total Trials

410

all time

Status Distribution
Active(125)
Completed(189)
Terminated(27)
Other(69)

Detailed Status

Completed189
Recruiting75
unknown67
Not yet recruiting26
Terminated23
Active, not recruiting19

Development Timeline

Analytics

Development Status

Total Trials
410
Active
94
Success Rate
89.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (1.9%)
Phase 12 (1.9%)
Phase 230 (27.8%)
Phase 331 (28.7%)
Phase 42 (1.9%)
N/A41 (38.0%)

Trials by Status

withdrawn41%
unknown6716%
completed18946%
not_yet_recruiting266%
recruiting7518%
suspended20%
active_not_recruiting195%
enrolling_by_invitation51%
terminated236%

Recent Activity

Clinical Trials (410)

Showing 20 of 410 trialsScroll for more
NCT03721341Phase 3

Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors

Active Not Recruiting
NCT06584409Not Applicable

Migraines Accepted Laser Acupuncture Compared in Blood Test of MMP2 and CGRP

Recruiting
NCT00003641Phase 3

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Completed
NCT03059485Phase 2

DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission

Active Not Recruiting
NCT03759717

Molecular and Cellular Characterization of Skull Base Tumors

Recruiting
NCT05640999Phase 2

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Recruiting
NCT07783594Phase 2

Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma

Not Yet Recruiting
NCT07825090

Association of ICU Admission Time, Age Stratification, and Clinical Frailty Scale With 30-Day Mortality in Geriatric Oncology Patients

Active Not Recruiting
NCT03602092

Observational Registry Data on GIST Patients

Completed
NCT07513324Phase 2

Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

Not Yet Recruiting
NCT07809178

China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm

Not Yet Recruiting
NCT07415603

PPV vs PVI in the Supine and Prone Position

Enrolling By Invitation
NCT05001087

A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)

Recruiting
NCT05065060

Parkinson Progression Marker Initiative Online (PPMI Online)

Recruiting
NCT07718802Not Applicable

Observational Approach Versus Surgical Intervention for Stones

Recruiting
NCT06596746

Neurodegenerative Diseases Progression Markers (MARKERS-NDD)

Recruiting
NCT05138393Not Applicable

Scoliosis-specific Exercises for Mild Idiopathic Scoliosis

Recruiting
NCT06817408

Dynamics of Organ Damage and Immune Exhaustion During Sepsis

Active Not Recruiting
NCT07775950Not Applicable

Research on Colorectal Cancer Recurrence Monitoring and Individualized Treatment Based on MRD

Recruiting
NCT07762924Phase 2

Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving Surgery

Recruiting

Drug Details

Intervention Type
OTHER
Total Trials
410